Despite decades of R&D effort, almost all biopharmaceuticals remain well beyond the reach of oral formulation technology. Today, these medicines are usually administered in a healthcare setting rather ...

Last year, the biotechnology industry celebrated the twentieth anniversary of the approval of the first true product of modern biotechnology—recombinant insulin (Humulin; Genentech, S. San Francisco, ...

With the increasing amount of available data, AI and machine learning have emerged as crucial tools for biopharmaceutical companies looking to remain competitive in the market. These tools are helping ...

Pfizer announced it will invest $465 million to build a new Modular Aseptic Processing Facility in Kalamazoo County, MI. The 400,000-square-foot facility, which will produce critical life-saving ...

The past three years have been interesting times for the biopharmaceutical industry. The first biosimilar product—Omnitrope (recombinant human growth hormone (rhGH); Sandoz, Holzkirchen, Germany) for ...

Biopharmaceuticals, also known as biologics, are a class of medicines produced using living systems such as microorganisms, plant or animal cells, or recombinant DNA technology. Unlike traditional ...

Since 2003, BioPlan Associates, Inc. has published an extensive annual survey of bioprocessing professionals. Since the first survey, which was started in collaboration with the American Society for ...

Using plant cells to make biopharmaceuticals is not a new idea. Pfizer’s Gaucher disease drug Elelyso (taliglucerase alfa), which is manufactured using carrot cells in culture—was approved in 2012.

Almost half of pharmaceutical industry profits continue to come from biopharmaceuticals. The current biopharmaceutical industry is estimated at more than $400 billion/year revenue and continues to ...